S. Karger AG

SHERPA: Unknown

People

  1. Bodei
    Bodei
  2. Drilon
    Drilon
  3. Motzer
    Motzer
  4. Abou-Alfa
    Abou-Alfa
  5. Chaganti
    Chaganti
  6. Lin
    Lin
  7. Tang
    Tang
  8. Clarkson
    Clarkson
  9. Janjigian
    Janjigian
  10. Marghoob
    Marghoob

Groups

  1. Department of Medicine (279)
  2. Solid Tumor Oncology Division (160)
  3. Hematologic Malignancies, Division of (107)
  4. Center for Hematologic Malignancies (103)
  5. Survivorship Research (59)
  6. Gastrointestinal Oncology Service (57)
  7. Sloan Kettering Institute Postdocs (55)
  8. Surgery (54)
  9. Sloan Kettering Institute Faculty (47)
  10. Thoracic Oncology (45)
Search Within
Formats
  1. Meeting Abstract (332)
  2. Journal Article (254)
  3. Book Section (20)
  4. Review (15)
  5. Conference Paper (10)
  6. Book Whole (1)
  7. Editorial (1)
Groups
  1. Department of Medicine (279)
  2. Solid Tumor Oncology Division (160)
  3. Hematologic Malignancies, Division of (107)
  4. Center for Hematologic Malignancies (103)
  5. Survivorship Research (59)
  6. Gastrointestinal Oncology Service (57)

More Groups

People
  1. Lisa Bodei (32)
  2. Alexander Drilon (23)
  3. Robert Motzer (23)
  4. Ghassan Abou-Alfa (18)
  5. Steven Hajdu (18)
  6. Oscar Lin (16)

More People

Years
  1. 2025 (3)
  2. 2024 (21)
  3. 2023 (37)
  4. 2022 (42)
  5. 2021 (31)
  6. 2020 (51)

More Years

Publications
  1. Oncology Research and Treatment (226)
  2. Cytogenetics and Cell Genetics (61)
  3. Acta Cytologica (58)
  4. Neuroendocrinology (51)
  5. Acta Haematologica (32)
  6. Onkologie (19)

More Publications

Results (633)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • POLO: Efficacy and health-related quality of life (HRQOL) with maintenance olaparib following first-line platinum-based chemotherapy (PBC) in patients (PTS) with a germline BRCA mutation and metastatic pancreatic cancer (MPC)
    Meeting Abstract

    Reinacher-Schick, A. C.; Kindler, H. L.; Hammel, P.; Reni, M.; Van Cutsem, E.; Mercade, T. M.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Oh, D. Y.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Checkmate 214 post hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma (ARCC) with sarcomatoid features (SRCC)
    Meeting Abstract

    Grimm, M. O.; McDermott, D. F.; Choueiri, T. K.; Motzer, R. J.; Frontera, O. A.; George, S.; Powles, T.; Donskov, F.; Harrison, M. R.; Rodriguez-Cid, J.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Association between depth of response (DepOR) and overall survival (OS): Exploratory analysis of nivolumab plus ipilimumab (N plus I) vs sunitinib (S) in patients with previously untreated advanced renal cell carcinoma (ARCC) in Checkmate 214
    Meeting Abstract

    Gruenwald, V.; Choueiri, T. K.; Rini, B. I.; Powles, T.; George, S.; Grimm, M. O.; McHenry, M. B.; Maurer, M.; Motzer, R. J.; Hammers, H. J.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • A phase 3, randomized, open-label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus CiSPLATiN (G plus C) for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (MiBC) (NiAGARA)
    Meeting Abstract

    Kubler, H. R.; Powles, T.; Meeks, J. J.; Galsky, M.; van der Heijden, M. S.; Nishiyama, H.; Al-Ahmadie, H.; Gupta, A.; Ye, J.; Donegan, S.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer
    Meeting Abstract

    Leyvraz, S.; Hyman, D. M.; van Tilburg, C. M.; Albert, C. M.; Tan, D. S.; Geoerger, B.; Farago, A. F.; Laetsch, T. W.; Kummar, S.; Doz, F.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • BEACON CRC: A randomized, phase 3 study of encorafenib (ENCO) and cetuximab (CETUX) with or without binimetinib (BiNI) vs. choice of either irinotecan or folfiri plus cetux in BRAF V600E-mutant metastatic colorectal cancer (mCRC)
    Meeting Abstract

    Vogel, A.; Hegewisch-Becker, S.; Prager, G.; Folprecht, G.; Stahl, M.; Kopetz, S.; Grothey, A.; van Cutsetn, E.; Yaeger, R.; Wasan, H.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Association of adverse events (AES) with efficacy outcomes for cabozantinib (C) in patients (PTS) with advanced hepatocellular carcinoma (AHCC) in the phase 3 CELESTIAL trial
    Meeting Abstract

    Waidmann, O.; Abou-Alfa, G. K.; Meker, T.; Cheng, A. L.; Cicin, I.; Bolondi, L.; Klumpem, H. J.; Chan, S. L.; Dadduzio, V.; Milwee, S.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Quality-adjusted life years accrued with cabozantinib in patients with advanced hepatocellular carcinoma (AHCC) in the CELESTIAL trial
    Meeting Abstract

    Venerito, M.; Abou-Alfa, G. K.; Mollon, P.; Meyer, T.; Cheng, A. L.; El-Khoueiry, A. B.; Kelley, R. K.; Baron, A. D.; Benzaghou, F.; Valcheva, V.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Efficacy of entrectinib in patients (PTS) with solid tumors and central nervous system (CNS) metastases: Integrated analysis from 3 clinical trials
    Meeting Abstract

    Overbeck, T.; Siena, S.; Doebele, R. C.; Shaw, A. T.; Karapetis, C. C.; Tan, D. S. W.; Cho, B. C.; Kim, D. W.; Ahn, M. J.; Krebs, M. G.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Matching-adjusted indirect comparison of cabozantinib (C) versus regorafenib (R) in advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Venerito, M.; Kelley, R. K.; Mollon, P.; Blanc, J. F.; Daniele, B.; Yau, T.; Cheng, A. L.; Valcheva, V.; Remiro Azocar, A.; Baio, G.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save